-
September 2026: This month in Huntington’s disease research
Latest News
-
Huntington’s disease therapeutics conference 2022 – Day 2
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2022
-
Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
A new imaging tool means that scientists can now directly measure the levels of the toxic huntingtin protein in animal models of Huntington’s disease, letting us see how well huntingtin lowering therapies are working in their brains
-
BAC to basics: a more accurate mouse model for Huntington's disease
A genetically-tweaked Huntington's disease mouse model shows a tendency for the CAG repeat to grow, just like we see in humans with the mutation.
-
Oral drug may change the story for huntingtin lowering
Researchers with PTC Therapeutics recently published exciting new findings – a promising new huntingtin lowering drug that can be taken as a pill. Will this change how we move forward with huntingtin lowering?
-
Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
The first round of findings from the halted tominersen huntingtin lowering trial, GENERATION-HD1, run by Roche were shared this week with the HD community. HDBuzz explains what they found and what’s next.
-
KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
In a much-needed bit of good news for the Huntington's disease community, Neurocrine Bioscience's KINECT-HD trial showed that treatment with valbenazine significantly reduced the involuntary movements called chorea
-
Updates from the EHDN Meeting 2021
Last month, HDBuzz attended the online European Huntington's Disease Network (EHDN) meeting. Read our summary of all the latest clinical trial updates.
-
Real talk: Q&A with Roche about GENERATION-HD1
The HDBuzz team sat down (virtually) for an in depth Q&A session with the team at Roche to answer questions about tominersen and the recent halting of the GENERATION-HD1 trial
-
Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing
A new system has been developed that allows researchers to fine-tune gene expression with oral drugs, work that provides a powerful tool for gene editing.
-
Unpacking recent gene therapy press
Voyager Therapeutics is shifting towards a new technology to deliver gene therapy and away from a planned HD clinical trial. But this could lead to less invasive drugs in the long run, and many other companies are working on HD gene therapies.
HDBuzz Trial Tracker
Show 10 more Show less
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
